Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

纽约 - 生物制药公司Anavex Life Sciences Corp. (NASDAQ:AVXL)宣布了其ANAVEX®3-71精神分裂症治疗的2期研究初步结果。该研究显示,该药物对与该疾病相关的关键脑电图 ...

Data of Blarcamesine confirm upstream SIGMAR1 activationPresented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease ...

On Friday, Anavex Life Sciences Corp (AVXL) stock saw a modest uptick, ending the day at $9.24 which represents a slight increase of $1.60 or 20.94% from the prior close of $7.64. The stock opened at ...

Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex” or ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) and keeping the price ...

About Anavex Life Sciences Corp.

Missling, PhD, President and Chief Executive Officer of Anavex. “We believe the scalable and convenient features of blarcamesine could reduce crucial barriers within the currently complex ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company ...